Use of parvovirus for eliminating cancer stem cells (CSCs)

US10525091B2 · kind B2 · utility

Assignees

• Deutsches Krebsforschungszentrum · DE
• RUPRECHT - KARLS - UNIVERSITÄT HEIDELBERG · DE

Inventors

• Jean Rommelaere · Heidelberg, DE
• Jeannine Lacroix · Heidelberg, DE
• Joerg Schlehofer · Leimen, DE
• Olaf Witt · Schriesheim, DE
• Elisabeth Hedwig Deubzer · Heidelberg, DE
• Sonja Kern · Würzburg, DE
• Christel Herold-Mende · Bammental, DE
• Karsten Geletneky · Heidelberg, DE
• Barbara Leuchs · Heidelberg, DE

Key dates

• Filing date: Jun 8, 2017
• Grant date: Jan 7, 2020
• Expiry date: Jun 8, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2750/14332
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.